Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Aldeyra Therapeutics Class Action Lawsuit
Business class action

Aldeyra Therapeutics Class Action Lawsuit

Analysis based on 21 articles · First reported Apr 24, 2026 · Last updated May 17, 2026

Sentiment
-50
Attention
4
Articles
21
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The class action lawsuit against Aldeyra Therapeutics could negatively impact its stock price and investor confidence due to allegations of misleading statements regarding drug trial results. For Bronstein, Gewirtz & Grossman, LLC, this action enhances its reputation as an investor-rights law firm.

Biotechnology Legal Services
Event Summary

A class action lawsuit has been filed against Aldeyra Therapeutics by Bronstein, Gewirtz & Grossman, LLC, on behalf of investors who purchased Aldeyra Therapeutics securities between November 3, 2023, and March 16, 2026. The lawsuit alleges that Aldeyra Therapeutics and its officers made false and misleading statements regarding the inconsistent results of clinical trials for its drug candidate, reproxalap. These inconsistencies allegedly rendered any positive findings unreliable, leading to materially false and misleading statements about Aldeyra Therapeutics's business, operations, and prospects. Investors are encouraged to join the lawsuit, with a deadline of May 29, 2026, to request appointment as lead plaintiff. Peretz Bronstein and Nathan Miller are key contacts for the law firm.

Key Actions
100 Bronstein, Gewirtz & Grossman, LLC filed class action lawsuit Aldeyra Therapeutics
Entities Involved
stock
Aldeyra Therapeutics
Aldeyra Therapeutics is the defendant in a class action lawsuit alleging that it made false and misleading statements regarding the clinical trials of its drug candidate, reproxalap, which could lead to significant financial and reputational damage.
Importance 100 Sentiment -70
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is the law firm that filed the class action lawsuit against Aldeyra Therapeutics, representing investors who allegedly suffered losses due to the company's misleading statements.
Importance 90 Sentiment 60
per
Peretz Bronstein
Peretz Bronstein is a founding partner of Bronstein, Gewirtz & Grossman, LLC, and is actively involved in the class action lawsuit against Aldeyra Therapeutics.
Importance 70 Sentiment 50
per
Nathan Miller
Nathan Miller is the Client Relations Manager at Bronstein, Gewirtz & Grossman, LLC, and is a contact person for investors interested in joining the class action lawsuit against Aldeyra Therapeutics.
Importance 60 Sentiment 40
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.